Back
ESC Professional Premium Access

Reversal agents to improve safety in patients treated with direct oral anticoagulants (DOACs).

Session: Problem-solving in antiplatelet therapy and anticoagulation
Topic: Cardiovascular Pharmacotherapy
Speaker: Professor A. Niessner (Vienna, AT)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Professor Alexander Niessner

Medical University of Vienna, Vienna (Austria)
9 presentations
2 followers

5 more presentations in this session

Reversal agents to improve safety in patients treated with antiplatelet P2Y12 inhibitors.

Speaker: Professor D. Bhatt (New York, US)

Access
Slides
Video
Like
Thumbnail

P2Y12 inhibitor monotherapy in patients undergoing PCI.

Speaker: Professor D. Angiolillo (Jacksonville, US)

Access
Slides
Video
Like
Thumbnail

Injectable and intravenous P2Y12 inhibitors in patients with acute myocardial infarction.

Speaker: Professor G. Montalescot (Paris, FR)

Access
Slides
Video
Like
Thumbnail

Factor XIa inhibitors: a new approach to anticoagulation in patients with cardiovascular disease.

Speaker: Doctor J. Weitz (Hamilton, CA)

Access
Slides
Video
Like
Thumbnail

Problem-solving in antiplatelet therapy and anticoagulation – discussion.

Access
Video
Like
Thumbnail

Access the full session

Problem-solving in antiplatelet therapy and anticoagulation

Speakers: Professor A. Niessner, Professor D. Bhatt, Professor D. Angiolillo, Professor G. Montalescot, Doctor J. Weitz
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources